

15 December 2017
EFPIA Japan

EFPIA Japan re-elected Ole Mølskov Bech as Chairman for the coming two year period

TOKYO—15 December 2017— EFPIA Japan announced today that Ole Mølskov Bech (President and Representative Director, Novo Nordisk Japan Ltd.) was re-elected as Chairman of EFPIA Japan for the period from 1 January 2018 to 31 December 2019.

Philippe Fauchet (GlaxoSmithKline K.K.) and Thorsten Poehl (Nippon Boehringer Ingelheim Co., Ltd.) will continue to serve in their positions as Vice Chairmen and will support Ole Mølskov Bech together with 6 other Board Directors. Along with this, Yoshitada Kimura (Novo Nordisk Japan Ltd.) and Rie Nakanishi (Novo Nordisk Japan Ltd.) are appointed as new Director General and new Secretary General respectively. The EFPIA Japan office will move to a new office in Novo Nordisk Pharma Ltd. Tokyo home office in Marounuchi.

“The changes in the drug pricing policy announced on November 22 will lead to significant changes in the business environment for research-driven global pharmaceutical companies”, says Ole Mølskov Bech, the Chairman of EFPIA Japan. “In order to ensure Japanese patient continue to have access to new innovative medicines as early as the rest of the world, EFPIA Japan will actively engage in transparent and constructive dialogue with the government and other stakeholders to facilitate the policy changes that are most harmful to innovation will be revisited.

EFPIA Japan Board Members as of 1 January 2018

Newly appointed board members during this year are noted

Chairman	Ole Mølskov Bech (Novo Nordisk Japan Ltd.)	
Vice Chairmen	Philippe Fauchet (GlaxoSmithKline K.K.)	
	Thorsten Poehl (Nippon Boehringer Ingelheim Co., Ltd.)	
Directors	Jacques Nathan (Sanofi K.K.)	
	Heike Prinz (Bayer Yakuhin, Ltd.)	
	Kazunari Tsunaba (Novartis Pharma K.K.)	
	Marc Dunoyer (AstraZeneca K.K.)	
	Stefan Sakurai (LEO Pharma K.K.)	
	Christopher Hourigan (Janssen Pharmaceutical K.K.)	New
Director General	Yoshitada Kimura (EFPIA Japan and Novo Nordisk)	New
Secretary General	Rie Nakanishi (EFPIA Japan and Novo Nordisk)	New

New EFPIA Japan Office (Effective from January 1, 2018)

Meiji Yasuda Seimei Bldg., 2-1-1 Marunouchi, Chiyoda-ku, Tokyo 100-0005

Tel: +81-3-6266-1354 Fax: +81-3-6266-1819

About EFPIA Japan:

Established in April 2002, EFPIA Japan represents 24 R&D-based European pharmaceutical companies operating in Japan. In 2016, combined sales from the member companies accounted for roughly 22% of the pharmaceutical market in Japan.

Mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan by early introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

About EFPIA:

EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 42 leading pharmaceutical companies, EFPIA provides the voice of 1,900 companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world.

For more information please visit:

<http://www.efpia.eu> (EFPIA)

<http://efpia.jp/English/index-e.html> (EFPIA Japan)

Inquiries to:

Noriko Okazaki, Committee Chair, Public Relations Committee, EFPIA Japan

Novo Nordisk Pharma Ltd.

2-1-1 Marunouchi, Chiyoda-ku, Tokyo 100-0005

TEL: 080-3508-3251

Mail: no@novonordisk.com

Tetsu Owari, Committee Vice Chair, Public Relations Committee, EFPIA Japan

Boehringer Ingelheim Japan, Inc.

ThinkPark Tower 2-1-1 Osaki, Shinagawa-ku, Tokyo 141-6017

TEL: 03-6417-2223

Mail : tetsuya.owari@boehringer-ingelheim.com